anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 229,381-229,410
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

229,381-229,410 of 303,780

filter-aware
14
The slide provides specific FX rate assumptions for EUR, GBP, CAD, and SEK for Q3 2023, Q3 2024, and Q4E 2024, along with sensitivity analysis for a 10% USD strengthening.Electronic Arts | Results Presentation Deck | 17 slides · Electronic Arts
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
15
The slide presents two separate tables: one for Q4 and one for the full year, detailing the impact of currency on year-over-year growth rates.Electronic Arts | Results Presentation Deck | 17 slides · Electronic Arts
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
16
Includes two separate tables: one by platform (Console, PC, Mobile) and one by product type (Full game, Live services).Electronic Arts | Results Presentation Deck | 17 slides · Electronic Arts
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
17
Standard financial disclosure slide for Electronic Arts.Electronic Arts | Results Presentation Deck | 17 slides · Electronic Arts
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
01
Slide 1
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations 1 hit
02
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations 1 hit
03
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations 1 hit
05
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Logic Chain1 hit
06
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Logic Chain1 hit
07
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
08
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
09
Scientific diagram illustrating the mechanism of antigen presentation and T cell maturation.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a biological diagram to explain the 'problem' of immune evasion in cancer therapy.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
12
The slide uses a process flow diagram to illustrate the 8-step manufacturing timeline.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
13
The slide uses a red border to highlight the RENB-DC11 row as the superior alternative.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
The diagram illustrates a complex supply chain process involving biopsy, manufacturing, and clinical administration.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
15
The slide uses a combination of a process diagram and dot plots to validate the model's performance.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
16
The slide presents two bar charts (weight and volume) and a grid of tumor photographs as visual proof of concept.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
17
Includes visual evidence of tumor size alongside quantitative bar charts with statistical significance markers.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
18
The table shows 0/3 incidence of metastasis/ascites in the RENB-DC11 group compared to high incidence in control groups.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
19
The slide presents two bar charts comparing control, tumor, tumor+mock, and tumor+TD groups under different treatment conditions (IL2 vs aCD16).Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
20
N=2-3 sample size indicated at bottom left.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
The slide demonstrates efficacy of RENB-DC11 in stimulating immune response (IFNg production) in a tumor model.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
22
The slide uses immunohistochemistry (brown staining) to visualize CD4+ T-cells, quantified in the bar chart.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
23
The slide uses immunohistochemistry images and a corresponding bar chart to demonstrate efficacy.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
24
This is a standard TPP (Target Product Profile) table used in biotech/pharma pitch decks.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
25
The slide outlines a clinical development plan with specific milestones for 2025 and 2026, focusing on safety and efficacy cohorts.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
26
The slide contrasts the traditional CRO outsourcing model with a direct management model to justify cost efficiency.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
28
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
01
Slide 1
Erasca | Investor Presentation Deck | 41 slidesErasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Setup1 hit